Predict, Prevent and Manage Severe Hyperbilirubinemia in Term and Late Preterm Newborns

1.     The ADAPTE Collaboration (2009). The ADAPTE Process: Resource Toolkit versions for Guideline Adaptation. Version 2.0 Available from: https://www.g-i-n.net/   2009.

2.     Amer YS, Elzalabany MM, Omar TI, Ibrahim AG, Dowidar NL. The 'Adapted ADAPTE': an approach to improve utilization of the ADAPTE guideline adaptation resource toolkit in the Alexandria Center for Evidence-Based Clinical Practice Guidelines. Journal of evaluation in clinical practice. 2015;21(6):1095-106.

3.     American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297-316.

4.     Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks' gestation: an update with clarifications. Pediatrics. 2009;124(4):1193-8.

5.     Bhutani VK, Committee on F, Newborn, American Academy of P. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2011;128(4):e1046-52

6.     Kemper AR, Newman TB, Slaughter JL et al. Clinical practice guideline revision: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics.2022; 150 (3): e2022058859.

7.     Ayyappan S, Philip S, Bharathy N, Ramesh V, Kumar CN, Swathi S, et al. Antioxidant status in neonatal jaundice before and after phototherapy. Journal of pharmacy & bioallied sciences. 2015;7(Suppl 1):S16-21.

8.     Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: for a safer first week. Pediatric clinics of North America. 2004;51(4):843-61.

9.     Maisels MJ. Epidemiology of neonatal jaundice. In: Maisels MJ, Watchko JF, editors. Neonatal jaundice. Amsterdam: Harwood Academic Publishers; 2000. p. 37–49.

10.  Ebbesen F, Andersson C, Verder H, Grytter C, Pedersen-Bjergaard L, Petersen JR, et al. Extreme hyperbilirubinaemia in term and near-term infants in Denmark. Acta paediatrica. 2005;94(1):59-64.

11.  Slusher TM, Zamora TG, Appiah D, Stanke JU, Strand MA, Lee BW, et al. Burden of severe neonatal jaundice: a systematic review and meta-analysis. BMJ paediatrics open. 2017;1(1):e000105.

12.  Basheer H, Makhlouf M, El Halawany F, Fahmy N, Iskander I. Screening for neonatal jaundice in El Galaa Teaching Hospital: A Egyptian Maternity Hospital – Can the model be replicated? Journal of Clinical Neonatology. 2017;6(2):128-33.

13.  Gamaleldin R, Iskander I, Seoud I, Aboraya H, Aravkin A, Sampson PD, et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics. 2011;128(4):e925-31.

14.  El Houchi SZ, Iskander I, Gamaleldin R, El Shenawy A, Seoud I, Abou-Youssef H, et al. Prediction of 3- to 5-Month Outcomes from Signs of Acute Bilirubin Toxicity in Newborn Infants. The Journal of pediatrics. 2017;183:51-5 e1.

15.  Mostafa MA et al. Knowledge of Neonatal Hyperbilirubinemia Among Primary Health Care Physicians: A Single-Center Experience. Clinical Medicine Insights: Pediatrics. 2019;  13: 1–5.

16.  Iskander I, Gamaleldin R, Kabbani M. Root causes for late presentation of severe neonatal hyperbilirubinaemia in Egypt. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2012;18(8):882-7.

17.  Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). Journal of perinatology : official journal of the California Perinatal Association. 2005;25(1):54-9.

18.  Amin S.B., Bhutani V.K., Watchko J.F. Apnea in acute bilirubin encephalopathy. Semin. Perinatal. 2014;38:407–411. doi: 10.1053/j.semperi.2014.08.003

19.  Shaprio S.M. Chronic bilirubin encephalopathy: Diagnosis and outcome. Semin. Fetal Neonatal Med. 2010;15:157–163

20.  Valinjkar SJ et al, Rebound hyperbiliurbinemia in neonates after phototherapy and factors affecting it. JMSCR 2017;5(3):19003-19014

21.  Taylor JA, Stout JW, de Greef L, Goel M, Patel S, Chung EK, et al. Use of a Smartphone App to Assess Neonatal Jaundice. Pediatrics. 2017;140(3).

22.  Hansen TW. The role of phototherapy in the crash-cart approach to extreme neonatal jaundice. Seminars in perinatology. 2011;35(3):171-4.

23.  Singla DA, Sharma S, Sharma M, Chaudhary S. Evaluation of Risk Factors for Exchange Range Hyperbilirubinemia and Neurotoxicity in Neonates from Hilly Terrain of India. International journal of applied & basic medical research. 2017;7(4):228-32.]\

24.  National Institute for Health and Care Excellence (NICE): Jaundice in the newborn under 28 days  [CG98.1]; 2010.

25.  National Institute for Health and Care Excellence (NICE): Addendum to Jaundice in newborn babies under 28 days. London:; 2016 May. (Clinical Guideline, No. 98.1.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK550520/

26.  Barrington KJ, Sankaran K, Canadian Paediatric Society, Fetus and Newborn Committee. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants | Canadian Paediatric Society: Canadian Paediatric Society; 2018 [updated 28/2/2018; cited 2018 15/6/2018]. Available from: https://www.cps.ca/en/documents/position/hyperbilirubinemia-newborn.

27.  Queensland Clinical Guidelines. Neonatal jaundice clinical guideline education presentation E22.7-1-V3-R27. Queensland Health. 2018.

28.  Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Canadian Medical Association Journal. 2010;182(18):E839-E42.

29.  Alshehri A, Almazrou S, Amer Y. Methodological frameworks for adapting global practice guidelines to national context int eh Eastern Mediterranean region. EMHJ, 2023;1:29(7):541-549

30.  Practice bulletin No. Practice bullitin no 181summary: prevention of RHD alloimmunization Obstet gynecol.2017;130(2): 481-483

31.  Vats K, Watchco JF. Coordinating care across the perinatal continuum in hemolytic disease of the fetus and newborn: the timely handoff of a postive maternal antierythrocyte antibody screen. J Pediatr. 2019; 214: 212-216

32.  Erdeve O. Management of neonatal jaundice in low-income and middle-income countries. BMJ Paediatr Open. 2020; 2;4(1):e000845

33.  Chen Yj, Yeh TH, Chen CM. Effect of breast feeding frequency on hyperbilirubinemia in breast fed term neonates. Pediatr Int. 2015;57(6):1121-1125

34.  Porter MLand Dennis BL.Hyperbilirubinemia in the term newborn. Am Fam Phys 2002;65(4):599-606

35.  Kaplan M, Kaplan E, Hammerman C et al, POst photherapy neonatal bilirubin rebound : a potential cause of significant hyperbiliurbinemia . Arch dis child 2006; 9(1):31-34

36.  Maayan-Metzger A, Schwartz T, Sulkes K, Merlob P. Maternal antiD prophylaxis during pregnancy does not cause neonatal hemolysis. Arch Dis Child Fetal Neonatal Ed. 2001; 84(1):F60–F62

37.  Flaherman VJ, Maisels MJ; Academy of Breastfeeding Medicine. ABM clinical protocol #22: guidelines for management of jaundice in the breastfeeding infant 35 weeks or more of gestation — revised. Breastfeed Med. 2017;12 (5): 250-257

38.   Maisels MJ, Clune S, Coleman K et al. The natural history of jaundice in predominantly breastfed infants. Pediatrics. 2014;134(2):e340-345

39.  Meek JY, Noble L. American Academy of Pediatrics, Section on breastfeeding. Breast feeding and use of human milk. Pediatrics 2022; 150(1): e2022057989

40.  Flaherman VJ, Schaefer EW, Kuzniewicz MW, Li SX, Walsh EM, Paul IM. Early weight loss nomograms for exclusively breastfed newborns. Pediatrics 2015; 135 (1) :e16-e23

41.  Newman TB, Liljestrand P, Escobar GJ. Jaundice noted in the first 24 hours after birth in a managed care organization. Arch Pediatr Adolesc Med. 2002;156(12):1244–1250

42.  Hulzebos CV, Vitek L, Coda Zabetta CD, et al. Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatr Res. 2021;90(2):272–276

43.  Wainer S, Parmar SM, Allegro D, Rabi Y, Lyon ME. Impact of transcutaneous bilirubinometry program on resource utilization and severe hyperbilirubinemia. Pediatr 2012; 129(1): 77-86. 

44.  Konana OS, Bahr TM, Strike HR, Coleman J, Snow GL, Christensen RD. Decision accuracy and safety of transcutaneous bilirubin screening at intermountain healthcare. J Pediatr. 2021;228:53–57

45.  Kuzniewicz MW, Park J, Niki H, Walsh EM, McCulloch CE, Newman TB. Predicting the need for phototherapy after discharge. Pediatrics. 2021;147(5): e2020019778

46.  Maisels MJ, Deridder JM, Kring EA, Balasubramaniam M. Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia. J Perinatol. 2009; 29(9):612–61733.

47.  Elsaie AL, Taleb M, Nicosia A et al. Comparison of end tidal cardon monoxide measurements with direct antiglobin tests in the managmeent of neonatal hyperbilirurbinemia . J Perinatol. 2020; 40(10): 1513-1517.

48.  Amegan-Aho KH, Segbefia CI, Glover NDO, Ansa GA, Afaa TJ. Neonatal Janudice: awareness , perception and preventive practices in expectant mothers. Ghana Med J.2019; 53(4):267-272.

49.  Olusanya BO, Imosemi DO, Emokpae AA. Differences between transcutaneous and serum bilirubin measurements in Black African neonates. Pediatrics. 2016;138(3):e20160907

50.  Engle WD, Jackson GL. Transcutaneous bilirubinometry. Semin Perinatol.2014; 34(7) :438-451.

51.  Radmacher PG, Groves FD, Owa JA, Ofovwe GE, Amuabunos EA, Olusanya BO, et al. A modified Bilirubin-induced neurologic dysfunction (BIND-M) algorithm is useful in evaluating severity of jaundice in a resource-limited setting. BMC pediatrics. 2015;15:28

52.  Watchko JF. Bilirubin-Induced Neurotoxicity in the Preterm Neonate. Clinics in perinatology. 2016;43(2):297-311

53.  Johnson L, Brown AK, Bhutani VK. BIND-a Clinical Score For Bilirubin Induced Neurologic Dysfunction In Newborns. Pediatrics. 1999;104(3):746-7.

54.  Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics. 1994;93(3):488–494

55.  Wallenstein MB, Bhutani VK. Jaundice and kernicterus in the moderately preterm infant. Clinics in perinatology. 2013;40(4):679-88.

56.  Amin SB, Saluja S, Kler N. Unbound bilirubin and acute bilirubin encephalopathy in infants born late preterm and term with significant hyperbilirubinemia. J Pediatrics 2024;266:113880.

57.  Noorulla F, Dedon R, Maisels MJ. Association of early direct bilirubin levels and biliary atresia among neonates. JAMA Netw Open. 2019;2(10):e1913321

58.  Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2017;64(1):154–168

59.  Tridente A, De Luca D. Efficacy of light-emitting diode versus other light sources for treatment of neonatal hyperbilirubinemia: a systematic review and meta-analysis. Acta Paediatr. 2012; 101(5):458–465

60.  Sachdeva M, Murki S, Oleti TP, Kandraju H. Intermittent versus continuous phototherapy for the treatment of neonatal non-hemolytic moderate hyperbilirubinemia in infants more than 34 weeks of gestational age: a randomized controlled trial. Eur J Pediatr. 2015;174(2):177–181

61.  Grabenhenrich J, Grabenhenrich L, B€ uhrer C, Berns M. Transcutaneous bilirubin after phototherapy in term and preterm infants. Pediatrics. sive phototherapy. Arch Pediatr Ado lesc Med. 2002;156(7):669–672 119.

62.  Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns.Pediatrics. 1994;93(3):488–494

63.   Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Archives of disease in childhood Fetal and neonatal edition. 2014;99(4):F325-31.

64.  Singh M. Vitamin K during infancy: current status and recommendations. Indian Pediatr. 1997 Aug;34(8):708-12. PMID: 9492399

65.  Drew JH, Wells R. The effect of drungs on albumin binding of bilirubin and on free bilirubin concentration as determined by flurescence quenching. Annals of pharmacology 1979;(13)9:486-560.

66.  Ahlfors CE, Shwer ML, Ford KB. Bilirubin-albumin binding in neonatal salicylate intoxication. Dev Pharmacol Ther. 1982;4(1-2):47-60.

67.  Shankaran S, Poland RL. The displacement of bilirubin from albumin by furosemide. J Pediatr. 1977 Apr;90(4):642-6.

68.  Pacifici GM, Marcini G. Clinical Pharmacology of Ceftriaxone in Neonates and Infants: Effects and Pharmacokinetics Systematic Review;2017  5751-5777

69.  Zecca E, Romagnoli C, De Carolis MP, Costa S, Marra R, De Luca D. Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics. 2009 Aug;124(2):480-4. doi: 10.1542/peds.2008-2433.    

70.  Martínez-Cruz CF, García Alonso-Themann P, Poblano A, Cedillo-Rodríguez IA. Hearing and neurological impairment in children with history of exchange transfusion for neonatal hyperbilirubinemia. Int J Pediatr. 2014;2014:605828.

71.  Ree, I. M. C., Smits-Wintjens, V. E. H. J., van der Bom, J. G., van Klink, J. M. M., Oepkes, D., & Lopriore, E. (2017). Neonatal management and outcome in alloimmune hemolytic disease. Expert Review of Hematology, 10(7), 607–616

72.  Watchko JF. Emergency release uncross-matched packed red blood cells for immediate double volume exchange transfusion in neonates with intermediate to advanced acute bilirubin encephalopathy: timely but insufficient? J Perinatol. 2018; 38(8):947–953

73.  Sproul A, Smith L. Bilirubin equilibra tion during exchange transfusion in hemolytic disease of the newborn. J Pediatr. 1964;65:12–26

74.   Valaes T. Bilirubin distribution and dynamics of bilirubin removal by exchange transfusion. Acta Paediatr (Stockh). 1963;52(suppl 149):57–69